Pyridam Farma Tbk PT banner

Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 282 IDR -2.08%
Market Cap: Rp3.2T

Multiples-Based Value

The Multiples-Based Value for Pyridam Farma Tbk PT (PYFA) under the Base Case is 598.25 IDR. Compared with the current market price of 282 IDR, the stock appears Undervalued by 53%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PYFA Multiples-Based Value
Base Case
598.25 IDR
Undervaluation 53%
Multiples-Based Value
Price Rp282
Worst Case
Base Case
Best Case

Multiples Across Competitors

PYFA Competitors Multiples
Pyridam Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Pyridam Farma Tbk PT
IDX:PYFA
3.2T IDR 1.1 -6.6 -51.3 -51.3
US
Eli Lilly and Co
NYSE:LLY
879.7B USD 13.5 42.6 28.8 30.7
US
Johnson & Johnson
NYSE:JNJ
574.1B USD 6.1 21.4 14.9 18.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.7 11.6 13.1
UK
AstraZeneca PLC
LSE:AZN
232B GBP 5.2 30 16.6 23.4
US
Merck & Co Inc
NYSE:MRK
295.2B USD 4.5 16.2 10 12.2
CH
Novartis AG
SIX:NOVN
236.4B CHF 5.1 20.7 12.8 16.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.2 7.6 8.9
US
Pfizer Inc
NYSE:PFE
154.1B USD 2.5 19.8 7.6 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
116.1B USD 2.4 16.5 7 8.6
P/E Multiple
Earnings Growth PEG
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average P/E: 21.9
Negative Multiple: -6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.6
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.4
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.7
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
1%
10.2
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.5
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBITDA: 50.4
Negative Multiple: -51.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.8
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.6
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Pyridam Farma Tbk PT
IDX:PYFA
Average EV/EBIT: 111.2
Negative Multiple: -51.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.7
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3
CH
Roche Holding AG
SIX:ROG
13.1
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
23.4
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
CH
Novartis AG
SIX:NOVN
16.5
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
2%
4.4
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.6
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett